home / stock / cytr / cytr news

CYTR News and Press, CytRx Corporation From 05/02/19

Stock Information
Company Name: CytRx Corporation
Stock Symbol: CYTR
Market: NASDAQ
Website: cytrx.com
Menu
CYTR CYTR Quote CYTR Short CYTR News CYTR Articles CYTR Message Board
Get CYTR Alerts

News, Short Squeeze, Breakout and More Instantly...
CYTR - CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S

LOS ANGELES , May 2, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has provided clinical guidance on arimoclomol developm...
CYTR - CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S

LOS ANGELES , April 29, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (CPH: ORPHA) has completed enrollment in its Phase 2/3 clinical tria...

CYTR - CytRx beats by $0.12, revenue in-line

CytRx (NASDAQ: CYTR ): FY GAAP EPS of -$0.29 beats by $0.12 . More news on: CytRx Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...

CYTR - CytRx Corporation Reports 2018 Financial Results

LOS ANGELES , March 29, 2019 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the full year ended December 31, 2018 and provided an overview of recent accomplishmen...
CYTR - CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

LOS ANGELES , March 12, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology treatment and diagnostics, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication...

CYTR - CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR(TM) Technology Targeting Delivery Directly to the Tumor

LOS ANGELES , Feb. 13, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientif...

CYTR - CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy

LOS ANGELES , Feb. 11, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted comments from an OncLive® article dated February 1, 2019 that an estimated majority of oncology patien...
CYTR - CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S

LOS ANGELES , Feb. 6, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, highlighted positive Phase 2/3 clinical trial data from arimoclomol licensee Orphazyme A/S (CPH: ORPHA). Orphazyme is curre...

Previous 10 Next 10